logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Costs, cost-effectiveness, and financing of tuberculosis treatment | Collections | MSF Science Portal
Costs, cost-effectiveness, and financing of tuberculosis treatment

Costs, cost-effectiveness, and financing of tuberculosis treatment

Tuberculosis (TB) is the world's deadliest infectious disease, and the leading killer of people with HIV. TB is curable, but it can be difficult to diagnose and tough to treat, especially for increasingly prevalent drug-resistant TB. In 2023, 22,700 people started TB treatment in MSF programs. Understanding the costs and cost-effectiveness associated with TB treatment and innovations, ranging from TB diagnostics and medications to TB care models, can help to plan resource needs and allocate resources effectively. Analyzing financing mechanisms can support developing sustainable funding models for TB control.

This collection spotlights articles by MSF and collaborators to analyze and document the costs of care, particularly diagnostics and medications.

Collection Content

Journal Article
|
Research

Trends in the availability and prices of quality-assured tuberculosis drugs: a systematic analysis of Global Drug Facility Product Catalogs from 2001 to 2024

Kohler S, Achar J, Mulder C, Sitali N, Paul N
2024-06-25 • Globalization and Health
2024-06-25 • Globalization and Health
BACKGROUND
The Global Drug Facility (GDF) of the Stop TB Partnership was launched in 2001 with the goal of increasing access to quality-assured tuberculosis (TB) drugs and products. ...
Journal Article
|
Research

Costs and import costs of past, present, and future TB drug regimens: a case study for Karakalpakstan, Uzbekistan

Kohler S, Sitali N, Achar J, Paul N
2022-11-23 • Journal of Public Health
2022-11-23 • Journal of Public Health
BACKGROUND
Tuberculosis (TB) drugs and their import are costly. We assessed how shorter TB drug regimens, which were non-inferior or superior in recent TB trials, can affect the cost...
Journal Article
|
Research

The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer, shorter, and short drug regimens for Karakalpakstan, Uzbekistan

Kohler S, Sitali N, Achar J, Paul N
2022-08-03 • PLOS Global Public Health
2022-08-03 • PLOS Global Public Health

Tuberculosis (TB) programs depend on a continuous supply of large amounts of high-quality TB drugs. When TB programs procure TB drugs from international suppliers, such as the Global ...

Journal Article
|
Research

Programme costs of longer and shorter tuberculosis drug regimens and drug import: a modelling study for Karakalpakstan, Uzbekistan

Kohler S, Sitali N, Achar J, Paul N
2022-03-21 • ERJ open research
2022-03-21 • ERJ open research
BACKGROUND
The introduction of new and often shorter tuberculosis (TB) drug regimens affects the cost of TB programmes.

METHODS
We modelled drug purchase and import cost...
Journal Article
|
Research

A framework for assessing import costs of medical supplies and results for a tuberculosis program in Karakalpakstan, Uzbekistan

Kohler S, Sitali N, Paul N
2021-08-25 • Health Data Science
2021-08-25 • Health Data Science

BACKGROUND

Import of medical supplies is common, but limited knowledge about import costs and their structure introduces uncertainty to budget planning, cost ma...

Journal Article
|
Research

Health system support and health system strengthening: two key facilitators to the implementation of ambulatory tuberculosis treatment in Uzbekistan

Kohler S, Asadov DA, Bründer A, Healy S, Khamraev AK,  et al.
2016-07-12 • Health Economics Review
2016-07-12 • Health Economics Review

Uzbekistan inherited a hospital-based health system from the Soviet Union. We explore the health system-related challenges faced during the scale-up of ambulatory (outpatient) treatme...

Journal Article
|
Research

Ambulatory tuberculosis treatment in post-Semashko health care systems needs supportive financing mechanisms

Kohler S, Asadov D, Brunder A, Healy S, Khamraev AK,  et al.
2014-12-01 • International Journal of Tuberculosis and Lung Disease
2014-12-01 • International Journal of Tuberculosis and Lung Disease
The tuberculosis (TB) control strategy in the Republic of Karakalpakstan, Uzbekistan, is being changed to decentralised out-patient care for most TB patients by the Government of Uzbekis...

See more collections

International Safe Abortion Day 2022

International Safe Abortion Day 2022
Unsafe abortion is a leading cause of maternal death, and the only one that is completely preventable. Yet over 30 million unsafe abortions occur each year, leading to at least 28,000 deaths and millions of serious complications—nearly all in low- and middle-income countries. MSF teams see these tragic consequences first-hand, treating thousands of patients every year with severe, potentially life-threatening effects from unsafe abortion. So in 2016 we launched a program to systematically implement safe abortion care (SAC), starting with ten pilot sites and then applying the lessons learned to scale up at projects across the globe. This Collection presents highlights of these efforts. Since our first publication on the need to provide SAC as a way of reducing maternal death and injury, several studies assessed the role of unsafe abortion in driving this suffering in specific contexts. Others described internal obstacles to providing SAC, operational solutions developed, and outcomes achieved. And we advocated for shifting towards community-led and self-managed SAC, particularly given new obstacles that emerged during the Covid-19 pandemic.
TB Union Conference 2022

TB Union Conference 2022
Innovation in preventing, diagnosing and treating drug-resistant tuberculosis (DR-TB) cannot come fast enough—especially given the ground lost due to the Covid-19 pandemic, and with only 1 in 3 people who have DR-TB now receiving care. The content collection linked below offers a snapshot of recent TB work by MSF and collaborators to help change this picture. The TB-PRACTECAL and endTB studies have delivered clear evidence for shorter, safer, more effective treatments against drug-resistant (DR)-TB. Faced with the many hurdles that lie ahead before these and other critical interventions can be widely accessible, other studies investigate patient/family-based models of care adapted to complex settings and neglected groups, including children. Last, several authors explore limited but potentially important options for expanding diagnosis and preventive treatment.
Neglected tropical diseases in 2023

Neglected tropical diseases in 2023

Each year hundreds of thousands of people die from a neglected tropical disease, while many more suffer serious illness or lifelong disability. Yet as we mark World Neglected Tropical Diseases (NTD) Day on 30th January 2023, global progress towards eliminating these diseases is threatened by shifting global health priorities and declining investment in the wake of the Covid-19 pandemic.


The content collection linked below offers a snapshot of MSF’s work over the past two years on managing some of the most deadly NTDs, finding better tools and models of care for highly affected populations, and advocating for greater access to care and increased global funding. Several authors describe our programs and lessons learned from a decade of treating snakebite victims in sub-Saharan Africa. Two studies evaluate shorter, less toxic treatment for visceral leischmaniasis, while a policy analysis proposes critical steps towards eliminating this horrific disease in East Africa. Last, reports from Sokoto, Nigeria describe the collaborative development of a comprehensive model of care for noma.

View All Collections